Company Overview and News
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Aircraft structures and parts provider Triumph Group has divested three more business units as the company’s slogs through a corporate turnaround, but financial analysts continue to call attention to the company’s cash generation ...
Triumph Group Inc.’s (TGI - Free Report) adjusted earnings from continuing operations in fourth-quarter fiscal 2018 (ended Mar 31, 2018) came in at $1.01 per share, which missed the Zacks Consensus Estimate of $1.02 by 1%. Reported earnings also declined 67.3% from $3.09 per share a year ago.
The following slide deck was published by Triumph Group, Inc. in conjunction with their 2018 Q4 earnings call.
Document UNITED STATES
Friday's tech rally may have set up stocks for more gains in the week ahead, although the market could be tugged at by geopolitical concerns, like trade war talk and Iran.
TGI is trading at an excessively cheap valuation due to a few years of poor management.
The report, now available on ASDReports, "Aircraft Doors Market by End User (OEM and Aftermarket), Application (Commercial (NBA, WBA, VLA, RTA, Business Jets) and Military (Transport Aircraft, Helicopter)), Door Type (Passenger, Cargo, Emergency, Access, Landing Gear) - Global Forecast to 2022", The aircraft doors market is projected to grow from USD 3.68 Billion in 2017 to USD 5.22 Billion by 2022, at a CAGR of 7.
Triumph Group, Inc. (NYSE:TGI) announced today that it has reached an agreement with Boeing to extend its current long-term agreement to supply composite detail and assembly parts for the Boeing 787 Dreamliner. Under the agreement, Triumph Aerospace Structures’ business based out of Milledgeville, Georgia will continue production of composite parts for the 787, section 47/48 fuselage to be shipped directly to Boeing’s North Charleston, South Carolina facility for integration into the aft body section of the airplane.
Document UNITED STATES
I have two portfolio's, the Dr. Jekyll portfolio is mostly growth and income oriented and is composed primarily of large cap companies that form the base of my equity holdings.
Parker-Hannifin is a Dividend King having increased its annual dividend for at least 50 consecutive years.
Triumph Group has reached an agreement with Gulfstream Aerospace to move Gulfstream G650 work from two Triumph facilities to Gulfstream’s site in Savannah, ...
April 3 (Reuters) - Aircraft parts maker Triumph Group Inc and Gulfstream Aerospace, a unit of General Dynamics Corp, plan to reallocate the assembly of components jointly produced at both companies to fewer and more automated plants.
According to the market research report, now available on ASDReports, "Aircraft Pumps Market by Pressure (500psi, 3000psi, 5000psi, 6500psi) Technology (Engine Driven, Electric Motor Driven, Rat Driven, Air Driven), Type (Fuel, Hydraulic, Lubrication, Cooling), End User, Application, Region - Global Forecast to 2023", The aircraft pumps market is estimated at USD 3.27 Billion in 2017 and is projected to reach USD 4.
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
2018-05-21 - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
as of ET